Money Matters

Fundraising Trends for Life Science Startups

Program

Join us for a forward-looking exploration of the life sciences fundraising landscape with our expert panel as they delve into the current state of fundraising for startups.

We’ll kick off the evening with a tour of the soon-to-be open BioLabs New Haven location and hear quick pitches from up-and-coming BioLabs residents.

3:00pm – Site Tours – BioLabs New Haven: 101 College St.

4:00-4:30pm – Registration: Brady Auditorium at 310 Cedar Street

4:30-5:00pm – BioLabs Resident Presentations: Brady Auditorium

5:00-6:00pm – Panel Discussion: Brady Auditorium

6:00-7:00pm – Networking & Refreshments: Brady Auditorium

Discussion

Our panelists, comprised of seasoned entrepreneurs, investors, and industry insiders, will analyze the existing challenges and opportunities in life science funding.

This panel is a must attend for entrepreneurs, investors, researchers, and professionals in life science who seek a nuanced understanding of the current fundraising climate and valuable foresight into the future.

Speakers

Morag Grassie, PhD - Director of the Blavatnik Fund for Innovation, Yale Ventures
Dr. Morag Grassie is the Director of the Blavatnik Fund for Innovation, previously serving as its Associate Director. Morag has over 30 years of experience in the pharma industry, entrepreneurship, and academic research. After graduating from Glasgow University with a BSc in molecular biology and Ph.D. in virology, she held positions in the pharmaceutical industry and a Yale biotech startup before joining Yale in 2018. Prior to this appointment, she was the Senior Associate Director for the Blavatnik Fund for Innovation at Yale and Associate Director, Business Development.
Lore Gruenbaum, PhD – VP, Therapy Acceleration Program, The Leukemia & Lymphoma Society
Dr. Lore Gruenbaum joined LLS in 2020 as the Vice President for the Therapy Acceleration Program (TAP), the LLS venture philanthropy program aiming to accelerate high-risk, innovative blood cancer therapeutics. She brings more than 20 years of drug discovery and clinical development experience to LLS working on small molecules, biologics, RNA-directed and cell therapies in multiple therapeutic areas including oncology, immunology, virology and neuroscience.
Mitra Miri, PhD - Principal, Osage Venture Partners
Mitra is a Principal on the life sciences team focusing on evaluating therapeutic investment opportunities. Previously, Mitra was an investor at Connecticut Innovations (CI), responsible for sourcing, diligencing and supporting opportunities across digital health, devices, diagnostics and therapeutics. Prior to CI, she was a Life Sciences Consultant in the healthcare practice at L.E.K. in NYC, where she worked with a range of biopharma companies from startups to large pharma across project types and therapeutic areas. She was also a Company Creation Fellow at Flagship Pioneering.
Alexia Kedves, MS - Senior Director, CSO Partner Team, Curie Bio
Driven by a passion for drug discovery, Alexia has dedicated her 20 year career to rigorously discovering new drugs and building biotech companies from the ground up – with a singular focus to bring novel therapies to patients in need. Since August of 2022, she has been part of the Curie.Bio CSO Partner team, enabling seed-stage founders to turn their therapeutics ideas into companies that are on the path to bring better treatments to patients.
Gregory Tietjen, PhD - CEO and Co-Founder, Revalia Bio
Gregory Tietjen is the CEO and co-founder of Revalia Bio, a company whose mission is to redefine organ donation to reinvent drug development. Gregory is a Renaissance man and a connector whose passion lies in building and inspiring diverse teams to tackle seemingly impossible problems. He is a galvanizer of people, dedicated to creating a better world by integrating multiple disciplines to enable transformative scientific breakthroughs.